Browse the evidence

The risk reduction from salt reduction is independent of baseline blood pressure, suggesting mechanisms beyond just blood pressure lowering.

Even if your blood pressure is normal, high salt intake can damage your heart muscle and arteries directly. Reducing salt protects your heart structure, not just your numbers.

Caloric restriction (CR) is an effective intervention that impacts aging, age-related pathologies, and longevity in model organisms such as mice and rats.

While this paper confirms caloric restriction extends longevity in mice and rats, it does not provide specific human dosing protocols. For humans, this suggests that avoiding overconsumption and maintaining a healthy weight may support healthy aging, but specific restriction protocols should be discussed with a healthcare provider.

Epigenetic clocks, such as the DNAm PhenoAge and DunedinPoAm, can predict biological age, lifespan, and risk of chronic disease.

Epigenetic clocks are emerging tools to measure biological aging. While not yet standard clinical practice, they may eventually help individuals track the impact of lifestyle changes on their biological age.

Sleep deprivation reduces the responsiveness of the circadian clock (SCN) to light, potentially mediated by adenosine blocking glutamate release.

Consistent sleep is required for your body to effectively respond to light cues for resetting your circadian rhythm. Sleep deprivation blunts this response.

Obstructive sleep apnea (OSA) is associated with an increased risk of incident heart failure in community-dwelling middle-aged and older men, but not in women.

If you are a man over 40, getting your sleep apnea treated is a critical step for heart health, even if you don't have other symptoms. The study shows that untreated OSA significantly increases the risk of developing heart failure. Women in this study did not show the same risk association, possibly due to later onset or hormonal protection, but men should prioritize diagnosis and treatment (like CPAP) to protect their heart.

The association between OSA and incident coronary heart disease (CHD) is weaker and less consistent than for heart failure, and was only nominally significant in men under 70 in this community-based study.

For men under 70, treating OSA may offer some protection against coronary heart disease, but the benefit is modest compared to its clear benefit for preventing heart failure. If you are over 70, the link to CHD is not statistically significant in this study. Focus on treating OSA primarily for heart failure prevention and overall sleep quality, rather than solely for CHD prevention.

Health-related stigma acts as a global barrier that impedes health-seeking behavior, engagement in care, and adherence to treatment across various conditions.

Health stigma is a major, documented barrier to getting care and sticking to treatment plans. It operates through social, cultural, and structural forces, not just individual psychology. To improve health outcomes, interventions must address these multi-level drivers rather than focusing solely on individual coping.

Activation of the gut microbiota-derived short-chain fatty acid receptor GPR43 in adipose tissue suppresses insulin signaling, thereby inhibiting fat accumulation and promoting energy expenditure.

To leverage this mechanism, prioritize dietary fiber intake to support gut bacteria that produce short-chain fatty acids (like acetate). These SCFAs activate GPR43 receptors in fat tissue, which helps suppress insulin-driven fat storage and promotes energy expenditure. This suggests that a high-fiber diet may support weight management through hormonal signaling, not just calorie reduction.

Hyperinsulinemia and insulin resistance are common pathophysiological features linking hypertension, obesity, and glucose intolerance, potentially explaining their ubiquitous association through mechanisms involving elevated intracellular sodium and increased peripheral vascular resistance.

If you have high blood pressure, especially if you are not obese, check your metabolic health. High insulin levels (hyperinsulinemia) and insulin resistance are strongly linked to hypertension, independent of obesity. Managing insulin sensitivity through diet and lifestyle may be as important for blood pressure control as reducing sodium intake.

Satellite cell fusion and the addition of new myonuclei are essential for muscle growth during early postnatal development but are not required for hypertrophy in adult skeletal muscle induced by most stimuli (e.g., reloading, androgens).

In adults, you can build muscle through increased protein synthesis without necessarily adding new nuclei (satellite cell fusion), especially with gradual training. Satellite cell fusion is more critical during development or after significant muscle damage.

Metformin is the first-line oral pharmacological treatment for Type 2 Diabetes Mellitus (T2DM) across all age groups, primarily by activating AMPK to inhibit hepatic gluconeogenesis and sensitizing peripheral tissues to insulin.

Metformin is the standard first-line medication for Type 2 Diabetes. It works by helping your liver produce less sugar and your body use insulin better. It typically lowers blood sugar by 1-2% without causing weight gain. If you have kidney issues, your doctor may adjust the dose or avoid it. Start with a low dose to minimize stomach upset.

In centenarians, gut microbiota composition shifts significantly toward facultative anaerobes (Proteobacteria, Bacilli) and decreases in symbiotic anti-inflammatory species (Faecalibacterium prausnitzii), which is associated with a highly inflamed status (inflammageing).

This research highlights that extreme longevity is associated with a unique gut microbiome profile characterized by lower diversity and higher levels of certain opportunistic bacteria, alongside lower levels of beneficial anti-inflammatory species. For general health, maintaining a diverse microbiome rich in symbiotic bacteria (like Faecalibacterium) through diet and lifestyle may help mitigate age-related inflammation, though specific interventions for centenarians are not yet defined.

Severe sleep-disordered breathing (AHI ≥30 events/h) is independently associated with increased all-cause and coronary artery disease mortality in men aged 40–70, mediated by intermittent hypoxemia rather than sleep fragmentation.

If you are a man between 40 and 70, getting tested for severe sleep apnea (AHI ≥30) is critical for longevity. The risk of death from heart disease and other causes doubles in this group, driven by low oxygen levels during sleep, not just poor sleep quality. Women and older men (>70) do not show the same strong link to mortality in this study, but severe cases in women still warrant attention.

In obese humans, circulating leptin levels are elevated while ghrelin levels are decreased, and the body exhibits leptin resistance, meaning high leptin fails to suppress food intake or increase energy expenditure as it does in lean individuals.

If you are obese, your body likely has high levels of leptin (the 'stop eating' hormone) and low levels of ghrelin (the 'start eating' hormone), but your brain has become resistant to these signals. This is why standard dieting often fails; your body fights back by ignoring the satiety signals. Understanding this resistance explains why simply 'trying harder' is physiologically difficult and why treatments must address the signaling pathway, not just hormone levels.

Leptin resistance in obesity is likely caused by defective transport of leptin across the blood-brain barrier (BBB) and/or downregulation of hypothalamic leptin receptors, rather than a lack of leptin production.

Standard leptin injections do not work for most obese people because the hormone cannot cross the blood-brain barrier efficiently or the brain receptors are downregulated. This is why 'leptin diets' or supplements are ineffective for common obesity. Effective interventions must either bypass the blood-brain barrier or target downstream pathways.

Ghrelin functions as a meal-initiation signal in humans, with preprandial increases correlating with hunger, and its levels are suppressed by food intake, although its role in long-term weight regulation is less clear than leptin's.

Ghrelin is your body's 'start eating' signal. It rises before meals and drops after. In obesity, ghrelin levels are actually lower than in lean people, but the system may be oversensitive. Understanding that hunger is a hormonal signal helps normalize the experience of hunger as a biological event, not a failure of will.

Immune system activation (e.g., by microbial challenges) triggers an inflammatory response that increases sleep duration and intensity, serving as a homeostatic regulation of slow-wave sleep.

When you are sick, your body's increased sleep drive is a biological mechanism to help you recover. Listen to this signal and allow yourself to rest, as sleep actively supports your immune defense during infection.

Disease-associated inflammation is a primary etiologic driver of malnutrition, causing anorexia, increased resting energy expenditure, and muscle catabolism, distinct from simple starvation.

In sick patients, malnutrition isn't just about not eating enough; the body's inflammatory response actively breaks down muscle and increases energy needs. Treating the inflammation is as important as providing nutrition.

High dietary fiber intake protects against colitis by increasing short-chain fatty acids (SCFAs) like acetate, which bind to GPR43 and GPR109A receptors on gut epithelial cells to activate the NLRP3 inflammasome and promote gut homeostasis.

To support gut health and reduce inflammation, prioritize a diet high in dietary fiber. This feeds gut bacteria to produce short-chain fatty acids (like acetate), which activate specific receptors (GPR43/GPR109A) on your gut lining. This process triggers a protective immune response (NLRP3 inflammasome) that maintains gut integrity and prevents inflammation.

Comprehensive, standardized databases of polyphenol content in foods are essential for accurately calculating population-level intake and studying the association between polyphenol consumption and chronic disease prevention.

To understand how polyphenols affect health, we need precise data on what is actually in our food. This database provides that by aggregating data from hundreds of studies, allowing researchers to better link specific polyphenol intakes to health outcomes like cardiovascular disease or diabetes prevention.

Visceral fat directly secretes interleukin-6 (IL-6) into the portal circulation, which correlates with systemic inflammation (CRP) and contributes to insulin resistance in obese humans.

For individuals with high abdominal fat, the location of fat matters biologically. Visceral fat actively releases inflammatory markers like IL-6 into the liver, which can drive insulin resistance. Reducing visceral fat through medical or lifestyle interventions may mitigate this inflammatory pathway.

The global prevalence of sarcopenia varies significantly (10-27%) depending on the diagnostic classification and measurement instrument used, with no single standardized criterion currently established.

Because there is no single standard for diagnosing sarcopenia, prevalence rates you see in media or different clinics will vary widely (10-27%). If you are concerned about muscle loss, ask your provider which diagnostic criteria they are using (e.g., EWGSOP2) and which tool (DXA or BIA) they used, as this determines the result. Consistency in testing is more important than comparing your result to a global average.

The prevalence of severe sarcopenia ranges from 2% to 9% globally, with higher rates observed in European studies using EWGSOP criteria compared to Asian/Oceanic studies using other classifications.

Severe sarcopenia, which combines low muscle mass with poor physical performance (like slow gait speed), affects 2-9% of the population depending on how it is measured. It is a stronger predictor of mortality than sarcopenia alone, so early identification using standardized performance tests is critical.

Dietary supplementation with butyrate and propionate protects against diet-induced obesity and improves glucose tolerance in mice, with butyrate and propionate also reducing food intake via FFAR3-independent mechanisms.

In a high-fat diet context, supplementing with butyrate and propionate (specifically at efficacious doses like 2.5-5% for butyrate and 2.2-4.3% for propionate in the diet) can prevent weight gain and improve glucose tolerance in mice. Butyrate also reduces food intake through mechanisms that do not rely on the FFAR3 receptor. These findings suggest that specific SCFA supplementation may be a viable strategy for metabolic health, though human translation requires further study.